Than Christian A, Adra Maamoun, Curtis Tom J, Khair Yasmine J, Milchem Hugh, Lee Sum-Yu C, Şanli Goktug, Smayra Karen, Nakanishi Hayato, Dannawi Zaher, Beck Belinda R
Faculty of Medicine, St. George's University of London, London SW17 0RE, UK.
University of Nicosia Medical School, University of Nicosia, 2417 Nicosia, Cyprus.
J Clin Med. 2024 Dec 9;13(23):7476. doi: 10.3390/jcm13237476.
: To investigate the effects of prolonged taping on patellofemoral pain (PFP). : A literature search of PubMed, EMBASE (Elsevier), CiNAHL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus, and Web of Science was conducted from database inception to 28 June 2024. Eligible studies reported PFP patients over 18 years of age undergoing an exercise protocol with additional taping that was maintained outside of exercise sessions (PROSPERO ID: CRD42023422792). : Seventeen studies met the eligibility criteria with 348 patients ( = 221 Kinesio taping, McConnell taping = 127). For pain, the Kinesio baseline scores were 5.73 (95% CI: 4.73-6.73, I= 97%), and the McConnell scores were 5.05 (95% CI: 3.82-6.28, I = 95%). At the combined recent follow-up, the Kinesio scores were 2.14 (95% CI: 1.11-3.18, I = 98%), and the McConnell scores were 2.58 (95% CI: 0.79-4.37, I = 98%). For functionality, the Kinesio baseline scores were 64.19 (95% CI: 53.70-74.68, I = 98%), and the McConnell scores were 68.02 (95% CI: 65.76-70.28, I = 0%). At the combined recent follow-up, the Kinesio scores were 84.23 (95% CI: 79.44-89.01, I = 95%), and the McConnell scores were 86.00 (95% CI: 83.82-88.17, I = 0%). The minimum clinically important difference (MCID) was achieved for both modalities at 6 weeks and beyond. : Prolonged taping that remains on PFP patients outside of isolated exercise sessions appears beneficial in reducing pain and increasing functionality.
探讨长期使用肌内效贴布对髌股疼痛(PFP)的影响。
对PubMed、EMBASE(爱思唯尔)、护理学与健康领域数据库(CiNAHL)、Cochrane对照试验中心注册库、Cochrane系统评价数据库、Scopus和Web of Science进行文献检索,检索时间从各数据库建库至2024年6月28日。纳入的研究报告了18岁以上的PFP患者在进行运动方案时额外使用了肌内效贴布,且在运动时段以外持续使用(国际前瞻性注册系统编号:CRD42023422792)。
17项研究符合纳入标准,共348例患者(肌内效贴布组221例,麦康奈尔贴布组127例)。疼痛方面,肌内效贴布组基线评分为5.73(95%置信区间:4.73 - 6.73,I² = 97%),麦康奈尔贴布组评分为5.05(95%置信区间:3.82 - 6.28,I² = 95%)。在综合近期随访时,肌内效贴布组评分为2.14(95%置信区间:1.11 - 3.18,I² = 98%),麦康奈尔贴布组评分为2.58(95%置信区间:0.79 - 4.37,I² = 98%)。功能方面,肌内效贴布组基线评分为64.19(95%置信区间:53.70 - 74.68,I² = 98%),麦康奈尔贴布组评分为68.02(95%置信区间:65.76 - 70.28,I² = 0%)。在综合近期随访时,肌内效贴布组评分为84.23(95%置信区间:79.44 - 89.01,I² = 95%),麦康奈尔贴布组评分为86.00(95%置信区间:83.82 - 88.17,I² = 0%)。两种贴布方式在6周及以后均达到了最小临床重要差异(MCID)。
对于PFP患者,在单独的运动时段以外持续使用肌内效贴布似乎有利于减轻疼痛并提高功能。